Founder’s Vision
ANKTIVA®
BCG
Clinical Trials
Find a Trial
Become a Trial
Investigator
License our Cells
Science
Platforms
Pipeline
Expanded Access
Research
Approach
Patients
Trial Investigators
Researchers
Condition
Bladder Cancer
Glioblastoma
HIV
Lynch / Colon Cancer
Non-Hodgkin Lymphoma
Ovarian Cancer
Human Papillomavirus
Non-Small Cell Lung Cancer
Company
About Us
Investors
News and Events
Contact
Careers
Select Page
Acceptance Requirements
Adult patients diagnosed with histologically-confirmed glioblastoma that has progressed after initial therapy or therapies
Must have previous first line treatment with at least radiotherapy and temozolomide.
Search for:
Recent Posts
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
ASCO 2025 Annual Meeting
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch